A Study on the Regulation Mechanism of ERK1/2 Promoting Proliferation and Inhibiting Apoptosis in Esophageal Squamous Carcinoma

doi:10.13560/j.cnki.biotech.bull.1985.2015.10.035

Abstract

Abstract: This study aims to explore the role of ERK1/2 MAPK in the regulation mechanism of cell proliferation and apoptosis concerning of esophageal squamous carcinoma（ESCC）. The results of plate colony, cell apoptosis and cycle revealed that the inhibition of ERK1/2 MAPK pathway eliminated the clone formation and proliferation of Eca109 cells, promoted cell apoptosis, and slowed down cell cycle; in addition, the inhibition of ERK1/2 MAPK pathway reversed the changes of proliferation, apoptosis and cycle induced by miR-21 overexpression. The results of qRT-PCR and Western blot showed that the inhibition of ERK1/2 MAPK pathway downregulated endogenous miR-21 expression, and also reversed the activation of ERK1/2 MAPK signal pathway induced by exogenous miR-21. The findings demonstrated that the inhibition of ERK1/2 MAPK pathway hindered Eca109 cell proliferation, promoted cell apoptosis, and retarded cell cycle via downregulation of miR-21 expression in Eca109 cell.

Key words: esophageal squamous cell carcinoma（ESCC）, ERK1/2 MAPK, Eca 109 cell proliferation, cell apoptosis, miR-21

Liu Fengxia, Liu Wenjuan, Li Jianyong, Chen Shenguo. A Study on the Regulation Mechanism of ERK1/2 Promoting Proliferation and Inhibiting Apoptosis in Esophageal Squamous Carcinoma[J]. Biotechnology Bulletin, 2015, 31(10): 242-248.

References

[1] 刘凤霞, 张盼盼, 李建勇, 等. MicroRNA-21通过正调控ERK1/2通路促进食管鳞状细胞癌的增殖和迁移[J]. 生物技术通报, 2013（12）：189-193.
[2] 刘凤霞, 牛淑亮, 李建勇, 陈胜国. MicroRNA-21在食管鳞状细胞癌中的作用及机制[J]. 中国公共卫生, 2014, 30（增刊）：11-15,
[3] Zheng ST, Huo Q, Tuerxun A, et al. The expression and activation of ERK/MAPK pathway in human esophageal cancer cell line EC9706[J]. Mol Biol Rep, 2011; 38（2）：865-72.
[4] 刘凤霞, 牛淑亮, 李建勇, 等. ERK1/2 MAPK 通路在Eca109细胞体外增殖和迁移中的作用及其机制[J]. 基础医学与临床, 2014, 34（3）：345-349.
[5]Shukla A, Hillegass JM, MacPherson MB, et al. ERK2 is essential for the growth of human epithelioid malignant mesotheliomas[J]. Int J Cancer, 2011, 129（5）：1075-1086.
[6]Ito M, Zhao N, Zeng Z, et al. Synergistic growth inhibition of anaplastic large cell lymphoma cells by combining cellular ALK gene silencing and a low dose of the kinase inhibitor U0126[J]. Cancer Gene Ther, 2010, 17（9）：633-644.
[7]Bessard A, Frémin C, Ezan F, et al. RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo[J]. Oncogene, 2008, 27（40）：5315-5325.
[8]Chen C, Chang YC, Lan MS, et al. Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ ERK1/2 and PI3K/Akt signaling pathways[J]. Int J Oncol, 2013, 42（3）：1113-1119.
[9]Cha JH, Choi YJ, Cha SH, et al. Allicin inhibits cell growth and induces apoptosis in U87MG human glioblastoma cells through an ERK-dependent pathway[J]. Oncol Rep, 2012, 28（1）：41-48.
[10]Burova EB, Smirnova IS, Gonchar IV, et al. Inhibition of the EGF receptor and ERK1/2 signaling pathways rescues the human epidermoid carcinoma A431 cells from IFNγ-induced apoptosis[J]. Cell Cycle, 2011, 10（13）：2197-2205.
[11]Yang TY, Chang GC, Chen KC, et al. Sustained activation of ERK and Cdk2/cyclin-A signaling pathway by pemetrexed leading to S-phase arrest and apoptosis in human non-small cell lung cancer A549 cells[J]. Eur J Pharmacol, 2011, 663（1-3）：17-26.
[12]Tong JS, Zhang QH, Huang X, et al. Icaritin causes sustained ERK1/2 activation and induces apoptosis in human endometrial cancer cells[J]. PLoS One, 2011, 6（3）：e16781.
[13]Yan DM, Dai RY, Duan CY, et al. Cross-talk between PI3K/Akt and MEK/ERK pathways regulates human hepatocellular carcinoma cell cycle progression under endoplasmic reticulum stress[J]. Zhonghua Gan Zang Bing Za Zhi, 2010, 18（12）：909-914.
[14]Dai R, Chen R, Li H. Cross-talk between PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death in human hepatocellular carcinoma cells[J]. Int J Oncol, 2009, 34（6）：1749-1757
[15]Zhang T, Li Y, Zhu Z, Gu M, et al. MEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells[J]. Mol Pharm, 2010, 7（5）：1576-1584.
[16]Li X, Lv Y, Yuan A, et al. Gastrin-releasing peptide promotes the growth of HepG2 cells via EGFR-independent ERK1/2 activation[J]. Oncol Rep, 2010, 24（2）：441-448.
[17]Zhang H, Li W, Sun S, et al. Inhibition of sphingosine kinase 1 suppresses proliferation of glioma cells under hypoxia by attenuating activity of extracellular signal-regulated kinase[J]. Cell Prolif, 2012, 45（2）：167-175.
[18]Glassmann A, Reichmann K, Scheffler B, et al. Pharmacological targeting of the constitutively activated MEK/MAPK-dependent signaling pathway in glioma cells inhibits cell proliferation and migration[J]. Int J Oncol, 2011, 39（6）：1567-1575.
[19]Zou ZQ, Zhang LN, Wang F, et al. The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells[J]. Mol Med Rep, 2012, 5（2）：503-508.
[20]Sabatel C, Malvaux L, Bovy N, et al. MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells[J]. PLoS One, 2011, 6（2）：e16979.
[21]Kwak HJ, Kim YJ, Chun KR, et al. downregulation of Spry2 by miR-21 triggers malignancy in human gliomas[J]. Oncogene, 2011, 30（21）：2433-2442.
[22]Huang TH, Wu F, Loeb GB, et al. Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion[J]. J Biol Chem, 2009, 284（27）：18515-18524.